Aspire Biopharma files Series A Convertible Preferred Stock with 80% discount conversion and price protection

Aspire Biopharma Holdings, Inc.

Filed Certificate of Designation for 25,000 shares of Series A Convertible Preferred Stock on Feb 2, 2026.
Conversion price at 80% of lowest closing price in 5 prior trading days; floor price at 20% of Nasdaq minimum price.
Beneficial ownership conversion cap at 4.99% (can increase to 9.99% with 61-day notice).
Holders get participation rights in 30% of future financings for 6 months; no voting rights.
Shares rank senior to common; price protection adjusts conversion price on lower-priced issuances.

item 5.03item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.